← Back to Search

Obeldesivir for COVID-19 (BIRCH Trial)

Phase 3
Waitlist Available
Research Sponsored by Gilead Sciences
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up first dose date up to day 5 plus 30 days
Awards & highlights

Summary

This trial will test a drug to see if it's safe & effective for treating COVID-19, and measure how it moves through the body.

Eligible Conditions
  • Coronavirus
  • COVID-19

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~first dose date up to day 5 plus 30 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and first dose date up to day 5 plus 30 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
COVID-19 Testing
Secondary outcome measures
Change from Baseline in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Nasal Swab Viral Load at Day 5
PK Parameter: Cmax of GS-441524
PK Parameter: Ctau of GS-441524
+10 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: ObeldesivirExperimental Treatment1 Intervention
Participants will receive obeldesivir 350 mg twice daily for 5 days.
Group II: PlaceboPlacebo Group1 Intervention
Participants will receive placebo twice daily for 5 days.

Find a Location

Who is running the clinical trial?

Gilead SciencesLead Sponsor
1,086 Previous Clinical Trials
847,962 Total Patients Enrolled
Gilead Study DirectorStudy DirectorGilead Sciences
343 Previous Clinical Trials
186,112 Total Patients Enrolled

Media Library

GS-5245 Clinical Trial Eligibility Overview. Trial Name: NCT05603143 — Phase 3
Coronavirus Research Study Groups: Obeldesivir, Placebo
Coronavirus Clinical Trial 2023: GS-5245 Highlights & Side Effects. Trial Name: NCT05603143 — Phase 3
GS-5245 2023 Treatment Timeline for Medical Study. Trial Name: NCT05603143 — Phase 3
~175 spots leftby Jul 2025